BioCentury
ARTICLE | Company News

AbbVie sales and marketing update

January 5, 2015 8:00 AM UTC

Pharmacy benefit manager Express Scripts Holding Co. (NASDAQ:ESRX, St. Louis, Mo.) granted exclusive formulary status to AbbVie’s Viekira Pak paritaprevir/ritonavir/ombitasvir plus dasabuvir to treat HCV genotype 1 infection. The move excludes Sovaldi sofosbuvir, Harvoni ledipasvir/sofosbuvir and Olysio simeprevir. Sovaldi, Harvoni and Olysio will continue to be available for patients who have already begun treatment regimens. Sovaldi will be available for patients with other HCV genotypes who have advanced liver disease. ...